ArticleOncology and therapy2025

Pharmacoeconomic Analysis of Brigatinib versus Alectinib in First‑Line Treatment of Anaplastic Lymphoma Kinase‑Positive Advanced Non‑Small‑Cell Lung Cancer in China.

Qingqing Chai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.